Upgrade to SI Premium - Free Trial

Seattle Genetics (SGEN) Reports Supplemental Biologics License Application Submission for ADCETRIS (Brentuximab Vedotin)

November 5, 2018 8:05 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles